EGFR and non-small cell lung carcinoma: The FLAURA study investigated the efficacy of Osimertinib in patients with EGFR T790M mutation-positive advanced NSCLC by comparing it to other standard EGFR TKIs, specifically gefitinib and erlotinib [17].